Clinical Trials · NCT03881995

Effects of Insulin Glargine and Lixisenatide on the Brain

TerminatedPhase 4Lixisenatide (Prohibited)
Phase
Phase 4
Recruitment status
Terminated
Sponsor
University Hospital Tuebingen
Enrollment
1
Start date
Mar 2019
Locations
1 site, Germany
Primary endpoint
Brain insulin sensitivity
View Lixisenatide compound reference